VANCOUVER, Canada–(BUSINESS WIRE)– Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 2, 2019 (the “Meeting”).
Shareholder Voting Results
The Shareholders voted on the following matters at this year’s Meeting.
Proposal 1 – Election of Directors
The nominees listed in Zymeworks’ proxy statement dated March 18, 2019 (the “Proxy Statement”) were elected as Directors of the Company. Detailed results of the votes are set out below:
| Proposal 1 | Outcome of the Vote | Votes by Ballot | |||||
| Election of Directors | Votes For | Votes Withheld | |||||
| Kenneth Hillan | Carried | 18,394,190 (99.92%) |
14,339 (0.08%) |
||||
| Natalie Sacks | Carried | 18,395,416 (99.93%) |
13,113 (0.07%) |
||||
Proposal 2 – Appointment of Auditors
The vote was carried for the Appointment of the Auditors, KPMG LLP. Detailed results of the votes are set out below:
| Proposal 2 | Outcome of the Vote | Votes by Ballot | |||||
| Votes For | Votes Withheld | ||||||
| Appointment of KPMG LLP | Carried | 23,430,739 (99.88%) |
28,799 (0.12%) |
||||
Full details of all proposals are fully described in the Proxy Statement available on the Company’s profile on SEDAR and on EDGAR and the detailed results of voting on each proposal are included in the Report of Voting Results filed on SEDAR and on EDGAR.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. The Company’s suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel AzymetricTM bispecific antibody currently in Phase 2 clinical development. The Company’s second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of ZW25 with Zymeworks’ proprietary ZymeLinkTM cytotoxic payload. Zymeworks is also advancing a deep preclinical pipeline in immuno-oncology and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through multiple strategic partnerships with eight global biopharmaceutical companies.
Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
Tiffany Tolmie
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Angela Bitting
(925) 202-6211
a.bitting@comcast.net
Related Article: Zymeworks Reports 2019 First Quarter Financial Results